Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Bayer
MOMA Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
C Ray Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aragon Pharmaceuticals, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Pharmaceutical K.K.
Eli Lilly and Company
IDEAYA Biosciences
OncoC4, Inc.
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
ARTBIO Inc.
Albert Einstein College of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Weill Medical College of Cornell University
Bayer
Arcus Biosciences, Inc.
Agenus Inc.
National Cancer Institute (NCI)
GlaxoSmithKline
Cellectar Biosciences, Inc.
Mayo Clinic
M.D. Anderson Cancer Center
University of California, San Francisco
Atavistik Bio, Inc
University of Oklahoma
Novartis
Baylor College of Medicine
Merck Sharp & Dohme LLC
City of Hope Medical Center
University of Utah
Alessa Therapeutics Inc.
Dana-Farber Cancer Institute
University of Texas Southwestern Medical Center